RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Drug attack on tough blood cancers
Disease control OngoingThis study is testing whether adding a new oral drug called seclidemstat to a standard chemotherapy (azacitidine) is safe and effective for patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The trial will first find the best dose and then se…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 04, 2026 00:36 UTC
-
New antibody drug enters human testing for Tough-to-Treat blood cancers
Disease control OngoingThis is a first-in-human study to find a safe dose of an experimental antibody drug called Hu8F4 for patients with advanced blood cancers like leukemia and myelodysplastic syndrome (MDS). The main goals are to check for side effects and see how the body processes the drug. The st…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for tough blood cancers: testing a Two-Drug attack
Disease control OngoingThis study is testing a new combination of two drugs, venetoclax and azacitidine, for patients with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has come back or stopped responding to standard treatment. The first part of the study aims …
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC